Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer"

Int J Cancer. 2022 Nov 15;151(10):1849-1850. doi: 10.1002/ijc.34207. Epub 2022 Aug 10.

Authors

Sarah M H Einerhand¹, Nick van Dijk², Michiel S van der Heijden^{2

3}, Bas W G van Rhijn¹

Affiliations

¹ Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.

PMID: 35815942
DOI: 10.1002/ijc.34207

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Transitional Cell*
Humans
Immunotherapy
Neoadjuvant Therapy
Platinum / therapeutic use
Urinary Bladder Neoplasms* / drug therapy

Substances

Platinum